AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell Sells 5,000 Shares

AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

AxoGen Stock Down 0.2 %

NASDAQ:AXGN traded down $0.04 on Friday, hitting $17.73. 636,905 shares of the company's stock traded hands, compared to its average volume of 557,396. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $21.00. The firm has a 50-day moving average price of $17.92 and a 200-day moving average price of $15.32. The company has a market cap of $786.22 million, a PE ratio of -55.41 and a beta of 1.02.

Institutional Investors Weigh In On AxoGen

Large investors have recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC raised its stake in shares of AxoGen by 166.0% in the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock valued at $15,729,000 after purchasing an additional 595,579 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in AxoGen by 2,912.3% in the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider's stock valued at $7,697,000 after acquiring an additional 530,775 shares during the last quarter. First Light Asset Management LLC boosted its holdings in AxoGen by 10.2% in the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock valued at $74,272,000 after acquiring an additional 416,499 shares during the last quarter. Parkman Healthcare Partners LLC bought a new position in AxoGen in the third quarter valued at about $5,789,000. Finally, Balyasny Asset Management L.P. acquired a new position in AxoGen in the fourth quarter valued at about $4,943,000. Institutional investors own 80.29% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on AXGN. Cantor Fitzgerald restated an "overweight" rating and issued a $24.00 price target on shares of AxoGen in a research note on Wednesday. Canaccord Genuity Group lifted their price target on shares of AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, AxoGen presently has an average rating of "Buy" and a consensus price target of $20.75.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.